

UC Irvine

UC Irvine Previously Published Works

Title

Development of a Protocol for Successful Palliative Care Consultation in Population of Patients Receiving Mechanical Circulatory Support.

Permalink

<https://escholarship.org/uc/item/3031k05g>

Journal

Journal of pain and symptom management, 54(4)

ISSN

0885-3924

Authors

Sinha, Shilpee
Belcher, Carey
Torke, Alexia
et al.

Publication Date

2017-10-01

DOI

10.1016/j.jpainsymman.2017.07.021

Peer reviewed

Brief Quality Improvement Report

Development of a Protocol for Successful Palliative Care Consultation in Population of Patients Receiving Mechanical Circulatory Support



Shilpee Sinha, MD, FACP, Carey Belcher, BSN, RN, CHPN, Alexia Torke, MD, MS,
Joycelyn Howard, MSN, RN, AGCNS-BC, Marco Caccamo, DO, James E. Slaven, MS, and
Irmira Gradus-Pizlo, MD

Indiana University (IU) School of Medicine (S.S., A.T., M.C., I.G.-P.), Indianapolis, Indiana; IU Health Physicians (S.S., C.B., A.T., J.H., M.C., I.G.-P.), Indianapolis, Indiana; IU Center for Aging Research (A.T.), Regenstrief Institute, Inc, Indianapolis, Indiana; IU Division of General Internal Medicine and Geriatrics (A.T.), Indianapolis, Indiana; Fairbanks Center for Medical Ethics (A.T.), IU Health, Indianapolis, Indiana; Daniel F. Evans Center for Spiritual and Religious Values in Healthcare (A.T.), IU Health, Indianapolis, Indiana; and IU Department of Biostatistics (J.E.S.), Indianapolis, Indiana, USA

Abstract

Background. In 2014, Joint Commission recommended palliative care (PC) engagement in ventricular assist device (VAD) implantation as destination therapy. Limited information is available on established PC protocols in the mechanical circulatory support (MCS) population.

Measures. The goals of our PC consultation were to document advance care planning (ACP) discussions and designate a surrogate decision maker (SDM) before MCS implantation. A retrospective analysis compared the frequency of PC consults, ACP discussion, and SDM before and after protocol implementation.

Intervention. A protocol was developed to conduct interdisciplinary PC consultations for the MCS population.

Outcomes. The percentage of PC consults placed before MCS implantation increased from 11 (17.2%) before protocol to 56 (96.6%) after protocol ($P < 0.0001$) and documented SDM increased from 26 (40.6%) before protocol to 57 (98.3%) after protocol ($P < 0.0001$).

Conclusions. Close PC/cardiology collaboration can substantially improve ACP discussions and SDM documentation in the MCS population. This multidisciplinary protocol facilitates successful PC consultations. *J Pain Symptom Manage* 2017;54:583–588. © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Key Words

Palliative care, mechanical circulatory support, advance care planning, surrogate decision maker, ventricular assist device

Background

Approximately 5.7 million Americans are currently diagnosed with heart failure with about 300,000 deaths per year. The prevalence has doubled over the last 25 years and is estimated to double again between 2030 and 2040 with the aging of the population.¹ When patients fail to respond to medical therapies, they are considered for advanced therapies such as heart transplant and mechanical circulatory support (MCS) devices. The two-year survival for

continuous-flow ventricular assist devices (VADs) in patients with low risk of complications has been shown to parallel that of cardiac transplantation, with patients reporting improved quality of life and functional capacity.² However, the majority of patients are at an increased risk of complications such as bleeding, infection, stroke, pump thrombosis, and respiratory failure among others.³ These can add significant stress and symptom burden to patients and their families. In addition, the patients getting these devices as

Address correspondence to: Shilpee Sinha, MD, FACP, Service Line Lead, Department of Palliative Care Assistant Professor of Medicine, Indiana University School of Medicine, 1633 N.

Capitol Avenue, MT 301, Indianapolis, IN 46202, USA.
E-mail: ssinha@iuhealth.org

Accepted for publication: July 7, 2017.

destination therapy (DT) will face the end of life with the VAD in place. Because of the need for advance care planning (ACP) and symptom management, the Centers for Medicare and Medicaid Services and The Joint Commission recommended in 2014 that a palliative care (PC) representative experienced with the VAD population be part of the interdisciplinary team based on patient and family needs.⁴

Swetz et al. proposed that a preparedness plan/ACP should be incorporated as part of a PC evaluation in this population.⁵ Advance care plans support care congruent to patients stated preferences.⁶ However, limited information is available on established PC protocols and metrics in the MCS population. Before our protocol intervention, very few patients receiving MCS at our institution had an ACP and rarely was the PC team involved in their care.

We developed and implemented a collaborative protocol between the PC team and the VAD team to ensure a multidisciplinary approach and timely PC consultation for all patients being considered for MCS implantation. Our protocol included all patients being evaluated for MCS regardless of whether they were DT or bridge to transplant (BTT) and even included total artificial heart patients. Because of the complex needs of this patient population, we incorporated an interdisciplinary team approach to our PC consultation. We sought to assess whether our collaborative approach resulted in a significant increase in the completion of an interdisciplinary PC consult and documentation of a surrogate decision maker (SDM).

Measures/Interventions

Intervention

On March 1, 2014, a standardized PC consultation protocol for all MCS candidates was implemented at our institution (Fig. 1). Our goal was to complete an interdisciplinary PC consultation on all patients before

MCS implantation. This protocol relied on close collaboration between heart failure specialists, cardiothoracic surgeons, and PC specialists to enable timely and effective PC evaluations. This was elemental to the success of our intervention and required active engagement in the planning stage from both teams. The clinical nurse coordinators from both the PC and cardiology teams were designated as main contact persons to ensure consistent, shared communication. We developed a routine quarterly meeting between the teams to provide ongoing feedback and review of the protocol. We also participated in the weekly interdisciplinary team discussions for patients either with implanted MCS or undergoing evaluation for the same.

Identification of Patients. The Cardiology team identifies patients being evaluated for MCS implantation and then generates an electronic medical record alert for PC consult before implant. The protocol includes both DT and BTT designated patients as well as total artificial heart patients. Including both DT and BTT patients is advantageous, as BTT patients can experience future complications that would remove them from transplant consideration.⁷

Content of the PC Consultation. After the cardiology team enters an electronic medical record alert for PC consultation, there is direct communication between nurse coordinators on both teams to share pertinent information before evaluation. PC consultations incorporate visits from the interdisciplinary team which includes PC trained physicians or advanced practice nurses, PC social worker, and PC chaplain.

Goals of the PC consultation are to facilitate identification and documentation of an SDM, to assist with ACP needs and to provide symptom-based physical, emotional, psychosocial, and spiritual support to the patient and/or their family members. For this report, ACP is defined as discussing medical care that a




Fig. 1. Palliative care and cardiology protocol diagram. ACP = advance care planning; MCS = mechanical circulatory support; PC = palliative care.

patient would like to receive in the future in the event the patient is unable to speak for him or herself. ACP discussions are documented in a formatted PC clinical note, and advanced directives, including the SDM document, are scanned and saved in a fixed section for advanced directive in the electronic medical record for easy access. The existing PC inpatient consulting team is primarily used as our resource, and therefore, patients are seen when admitted to the hospital often when undergoing preparation for implantation. The PC team is not always part of the early decision-making process as patients are often admitted with the intent to implant an MCS.

Our model includes an interdisciplinary and ongoing assessment by the PC clinician as well as the PC social worker and chaplain to address psychosocial and spiritual needs both before and after implantation. Visits are tailored according to the identified needs of the patient and family. In several cases, we have identified psychosocial and spiritual needs to be greater than the medical needs. Examples of psychosocial needs include adjustment to illness, grief over loss of independence, and caregiver support.

Our PC consultation is not just limited to a preoperative consultation. After the initial evaluation, the PC team continues to work collaboratively with the cardiac team throughout MCS workup and after MCS implantation with regular patient visits. The protocol relies on PC involvement both before and after device implantation to ensure continuity of care and is not limited to ACP alone.

Measures

A retrospective pre/post analysis was done to assess this protocol and its quality improvement impact. Chart review was performed on all patients who received MCS devices at our academic health center. The analysis included two observation periods: before the implementation of the standardized PC consultation protocol (pre-PC protocol) from January 1, 2012, to February 28, 2014, and after implementation (post-PC protocol) from March 1, 2014, to December 31, 2015. Approval was obtained from the Indiana University Institutional Review Board for future study implications.

Patient demographic characteristics were obtained from the retrospective chart review. Detailed information about involvement of the PC team was also recorded, including presence of PC consult before and after implantation, presence of documented SDM before and after MCS implantation, members of the PC team involved in the patient's care before and after MCS implantation, physical location of death for deceased patients, and PC team or hospice involvement at the time of death.

Statistical Analysis

For both demographic and participant outcomes, Student's t-tests were performed for continuous variables to look for differences between groups (pre- vs. post-PCC protocol). All analytic assumptions were verified, and Wilcoxon nonparametric tests were performed when continuous variables were determined to be nonlinear. For categorical variables, Fisher's exact tests were used to determine if there was significant heterogeneity between groups, due to low cell counts. All analyses were performed using SAS v9.4 (SAS Institute, Cary, NC).

Outcomes

Demographics

There were 122 patients implanted with MCS devices from January 1, 2012, to December 31, 2015, with 64 pre-protocol and 58 post-protocol patients (Table 1). The group before protocol implementation included more women (39.1% vs. 20.7%, $P = 0.0315$) and small differences in marital status ($P = 0.0497$). The two groups were similar in other demographics. Mean age was 57.73 ± 12.85 years and 54.86 ± 12.85 years for pre- and post-protocol groups, respectively. Hospital lengths of stay were skewed, and so are given with median (range), and are 30.6 days (13.2–148.9) and 30.1 days (0.4–95.0), respectively.

Protocol Results

The total overall percentage of PC consults placed before MCS implantation was 54.9% (67) from 2012 to 2015. The percentage of PC consults placed before MCS implantation increased from 17.2% (11) before protocol to 96.6% (56) after protocol ($P < 0.0001$) and documented SDM increased 40.6% (26) before protocol to 98.3% (57) after protocol ($P < 0.0001$; Table 1). Of note, the proportion of documents completed by the PC team (vs. previously completed) did not change (80.8% vs. 79.0%, $P = 0.8487$) as shown in Table 1.

The use of the multidisciplinary PC team members in the MCS population before and after implant increased across all disciplines after protocol ($P < 0.0001$). However, the distribution of team member use before and after implant was found not to be statistically different ($P < 0.10$), suggesting that team members continued their involvement after implant (Table 1).

In the total patient sample ($n = 122$), 31 patients (25.4%) were deceased as of data collection. There were no statistical differences in the use of hospital-based palliative care ($P = 0.2930$) or hospice care ($P = 0.2955$) at the end of life between the pre-protocol ($n = 19$; 29.7%) and post-protocol ($n = 12$;

Table 1
Patient Demographics and Results

| Patient Characteristics and Results | Pre-PC Protocol (n = 64) | | Post-PC Protocol (n = 58) | | Total (N = 122) | | P-Values ^a |
|---|--------------------------|------------------|---------------------------|--------------|-----------------|------------------|-----------------------|
| | n | % | n | % | n | % | |
| Age (range, mean) | | 24–75, 57.73 | | 26–78, 54.86 | | 24–78, 56.37 | 0.2200 |
| Hospital length of stay (range, mean) | | 13.2–148.9, 34.6 | | 0.4–95, 34.2 | | 0.4–148.9, 34.43 | 0.9837 |
| Sex | | | | | | | 0.0315 |
| Male | 39 | 60.9 | 46 | 79.3 | 85 | 69.7 | |
| Female | 25 | 39.1 | 12 | 20.7 | 37 | 30.3 | |
| Race | | | | | | | 0.6771 |
| Caucasian | 49 | 76.6 | 46 | 79.3 | 95 | 77.9 | |
| African American | 14 | 21.9 | 9 | 15.5 | 23 | 18.9 | |
| Native Hawaiian or Pacific Islander | 0 | 0 | 1 | 1.7 | 1 | 0.8 | |
| Hispanic | 0 | 0 | 1 | 1.7 | 1 | 0.8 | |
| Unknown | 1 | 1.6 | 1 | 1.7 | 2 | 1.6 | |
| Education | | | | | | | 0.8551 |
| Some high school | 5 | 7.9 | 7 | 12.5 | 12 | 9.8 | |
| High school/GED | 32 | 50.8 | 26 | 46.4 | 8 | 6.6 | |
| <4 yrs college | 18 | 28.6 | 17 | 30.4 | 19 | 15.6 | |
| College/graduate degree | 8 | 12.7 | 6 | 10.7 | 11 | 9.0 | |
| Marital status | | | | | | | 0.0497 |
| Single | 2 | 3.1 | 10 | 17.2 | 12 | 9.8 | |
| Significant other | 4 | 6.3 | 5 | 8.6 | 9 | 7.4 | |
| Married | 45 | 70.3 | 35 | 60.3 | 80 | 65.6 | |
| Separated | 2 | 3.1 | 2 | 3.4 | 4 | 3.3 | |
| Divorced | 7 | 10.9 | 6 | 10.3 | 13 | 10.7 | |
| Widowed | 4 | 6.3 | 0 | 0 | 4 | 3.3 | |
| Type of therapy | | | | | | | 0.8543 |
| BTT | 25 | 39.1 | 24 | 41.4 | 49 | 40.2 | |
| DT | 39 | 60.9 | 34 | 58.6 | 73 | 59.8 | |
| MCS implanted | | | | | | | 0.0091 |
| HeartWare | 12 | 18.8 | 23 | 39.7 | 35 | 28.7 | |
| HeartMateII | 51 | 79.7 | 32 | 55.2 | 83 | 68.0 | |
| HeartMateIII | 0 | 0 | 2 | 3.4 | 2 | 1.6 | |
| TAH | 1 | 1.6 | 1 | 1.7 | 2 | 1.6 | |
| PC consult before implant | 11 | 17.2 | 56 | 96.6 | 67 | 54.9 | <0.0001 |
| SDM documented before implant | 26 | 40.6 | 57 | 98.3 | 83 | 68.0 | <0.0001 |
| SDM documents | | | | | | | 0.8487 |
| Completed with PC team | 21 | 80.8 | 45 | 79.0 | 66 | 79.5 | |
| Preexisting documents | 5 | 19.2 | 12 | 21.1 | 17 | 20.5 | |
| PC team member involvement ^b | | | | | | | <0.10 |
| Before MCS implant | | | | | | | |
| Physicians | 10 | 15.6 | 41 | 70.7 | 51 | 41.8 | <0.0001 |
| Advanced practice nurses | 6 | 9.4 | 27 | 46.6 | 33 | 27.0 | <0.0001 |
| Social work | 9 | 14.1 | 44 | 75.9 | 53 | 43.4 | <0.0001 |
| Chaplain | 7 | 10.9 | 35 | 60.3 | 42 | 34.4 | <0.0001 |
| After MCS implant | | | | | | | |
| Physicians | 5 | 7.8 | 33 | 56.9 | 38 | 31.1 | <0.0001 |
| Advance practice nurses | 5 | 7.8 | 26 | 44.8 | 31 | 25.4 | <0.0001 |
| Social work | 9 | 14.1 | 50 | 86.2 | 59 | 48.4 | <0.0001 |
| Chaplain | 7 | 10.9 | 35 | 60.3 | 42 | 34.4 | <0.0001 |

PC = palliative care; BTT = bridge to transplant; DT = destination therapy; MCS = mechanical circulatory support; TAH = total artificial heart; SDM = surrogate decision maker.

^aP-values are from Fisher's exact tests for categorical variables, Student's t-test for age, Wilcoxon nonparametric test for LOS.

^bP-value from nonparametric two-sample Kolmogorov-Smirnov test.

20.7%) samples. The majority of patients both before protocol (84.2%) and after protocol (83.3%) died in the hospital. Only two patients both before and after protocol died at home ($P = 0.6547$).

Discussion

We developed a collaborative protocol between the PC and cardiology teams to include all patients undergoing evaluation for MCS. This was associated with near 100% rate of PC evaluations completed before

MCS implantation and a substantial increase in the number of patients with a documented SDM. The Joint Commission has recommended the involvement of PC evaluation for DT VAD implants.⁴ However, our protocol was designed to include all MCS patients given the knowledge that BTT patients have similar needs for ACP and may get removed from the transplant list based on complications or clinical changes.⁷

We used our electronic medical record system effectively to generate an automated PC consult trigger

when a patient was identified. This guaranteed notification of the PC consultation request for the MCS population. The electronic medical record was also used for documentation and storage of ACP/SDM documents in a defined location to ensure easy and consistent accessibility. We had a standardized structure for documenting the ACP that was influenced by the preparedness plan as suggested by Swetz et al.⁵ The basic requisite was to document patient preferences for ACP, name and contact information for SDM, and any symptoms needing to be addressed. SDM documentation was used as a metric for our protocol success because the goal of ACP is to include patients in shared decision making and provide care in accordance with their preferences. Identifying an SDM is an important step to safeguard that patient wishes for care are honored.^{8,9}

While undergoing MCS implantation, patients are under anesthesia for a significant time period and on mechanical ventilation postoperatively. During this time period, patients are unable to speak for themselves. Patients may suffer minor or major complications leaving them incapacitated and unable to have complex medical discussions. Surrogacy laws vary by state, and in Indiana, the laws are particularly complex, with multiple family members having equal authority in decision making. Patients are often unaware of these laws. Even with a well-developed ACP, surrogates are needed to interpret patient preferences and translate them into concrete medical decisions. By identifying a legal SDM and including the SDM in the ACP discussions, the goal is to ensure the patient's wishes are honored in such an event.

The development of this protocol identified a growing need for outpatient follow-up to provide symptom management and ongoing palliative support. Based on these observations, an outpatient component to the collaboration has been established.

Although the Joint Commission recommends a PC representative who has experience with the VAD patient population be part of the interdisciplinary team, we provided a multidimensional approach of care to the patients across the spectrum including needs beyond ACP. We were additionally able to provide this service to all patients under evaluation for MCS.

Challenges were identified in the implementation of the protocol. One challenge was how to allocate resources from an already busy service toward this specialized group of patients. We limited this challenge by tailoring visits based on needs after the first evaluation and by frequent chart reviews and close collaboration with the primary cardiology team and other staff. In addition, by using our multidisciplinary approach effectively, we were able to limit the impact of this challenge on our PC service. Limited time constraints within a hospital stay during MCS workup

added to the overwhelming amount of new staff members introduced to the patient and their family were also a challenge. An addition of an outpatient clinic for earlier counseling and decision making was identified as beneficial. Future studies could replicate the protocol at multiple centers using similar metrics for success. Another area to explore is how PC can benefit patients through psychosocial and symptom support during the course of MCS implantation. A similar model can be looked at in patients with serious illness who are considering discrete interventions such as renal replacement therapy, organ transplant, and any major preoperative evaluations. Future research could also ascertain protocol impact on a patient's end-of-life experience and care including the use of PC and hospice services.

Limitations

The observations presented are from a relatively small cohort limited to one institution and as such would need to be validated by implementation in different settings. In addition, the data were retrospective and based on chart review, and ongoing evaluation of this protocol would be beneficial. The mortality numbers in the given cohort were not large enough to allow adequate assessment of benefits the PC team provided in end-of-life care. In addition, the cohort is too small to allow comparisons between BTT and DT patients.

Conclusions

The results demonstrated that at a single institution, an automated PC consult protocol and interdisciplinary consult approach for MCS candidates results in completion of a PC consult and successful documentation of an SDM with a high success rate. Close collaboration and a multidisciplinary approach were found to be critical and fundamental to the success of this protocol. An integral element of the protocol was the communication between the team clinical nurse coordinators. An automated consultation trigger via the electronic medical record along with documentation within the electronic medical record proved beneficial. The desired outcome from the multidisciplinary approach was to provide care concordant with stated goals, reduced symptom burden, and to improve SDM education and documentation.

Disclosures and Acknowledgments

The authors would like to acknowledge Jeanette Pickrell, BSN, RN; Elizabeth Gleissner, BSN, RN; and

Teresa Barkwill, BSN, RN for their essential role in the protocol as VAD Coordinators. The authors would also like to thank Greg Sachs for his advisory role.

The authors have no disclosures. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013;6:606–619.
2. Takeda K, Takayama H, Kalesan B, et al. Long-term outcome of patients on continuous-flow left ventricular assist device support. *J Thorac Cardiovasc Surg* 2014;148:1606–1614.
3. Kilic A, Acker MA, Atluri P. Dealing with surgical left ventricular assist device complications. *J Thorac Dis* 2015;7:2158–2164.
4. The Joint Commission. Modified: ventricular assist device destination therapy requirements. *Jt Comm Perspect* 2014;34:6–7.
5. Swetz KM, Freeman MR, AbouEzzeddine OF, et al. Palliative medicine consultation for preparedness planning in patients receiving left ventricular assist devices as destination therapy. *Mayo Clin Proc* 2011;86:493–500.
6. Silveira MJ, Kim SY, Langa KM. Advance directives and outcomes of surrogate decision making before death. *N Engl J Med* 2010;362:1211–1218.
7. Owens AT, Jessup MR. Should left ventricular assist device be standard of care for patients with refractory heart failure who are not transplantation candidates? *Circulation* 2012;126:3081–3087.
8. Torke AM, Sachs GA, Helft PR, et al. Scope and outcomes of surrogate decision making among hospitalized older adults. *JAMA Intern Med* 2014;174:370–377.
9. DeMartino ES, Dudzinski DM, Doyle CK, et al. Who decides when a patient can't? Statutes on alternate decision makers. *N Engl J Med* 2017;376:1478–1482.